Lab21 announces publication of syphilis diagnostic patent
Cambridge, UK – 21st July 2009: Lab21, the healthcare diagnostics company, is pleased to announce the publication of its international patent application covering the use of syphilis antigens in immunodiagnostic applications.
Lab21 scientists discovered that chemical treatment of recombinant syphilis antigens improved the ability of these proteins to discriminate between infected and non-infected samples. This information has now been successfully incorporated into Lab21’s syphilis detection products with significant improvement in the specificity of its assays.
Colin Knox, Head of Immunodiagnostic Development at Lab21, explained: “The technology we have developed means that we can now provide improved specificity without compromising the high level of sensitivity required by such a test. The real value of this technology is that it significantly improves the performance of our assays in screening protocols for blood-borne pathogens. This combination of high sensitivity and high specificity has been a major issue in the syphilis EIA market and we believe that the panel of Lab21 syphilis assays now meets the highest standards required by our customers.”
Hayden Jeffreys, Head of Sales and Marketing Diagnostic Products at Lab21, commented: “This improvement in the syphilis assay is highly relevant to routine diagnostic laboratories both in Europe and the US and demonstrates our significant investment in the enhancement of our immunodiagnostic portfolio. We anticipate the regular launch of new proprietary assays as well as further enhancements of our cutting-edge products. An example of this will be the launch of our new cytomegalovirus assay, which will be available from next month and will bring the benefits of higher sensitivity and earlier detection of CMV infection.”